From the Journals

April 30, 2026

Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma

At the first and second interim analyses of the phase III LITESPARK-011 trial, treatment with the novel first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan plus lenvatinib im...

The ASCO Post

April 30, 2026

Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma

The ASCO Post

April 30, 2026

Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma

The ASCO Post

April 29, 2026

MIBC: Pembrolizumab With Trimodal Therapy for Bladder Preservation

Pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiation therapy and maximal transurethral resection may be safe and feasible in patients with muscle-invasive bladder ca...

The ASCO Post

April 29, 2026

MIBC: Pembrolizumab With Trimodal Therapy for Bladder Preservation

The ASCO Post

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.

April 29, 2026

MIBC: Pembrolizumab With Trimodal Therapy for Bladder Preservation

The ASCO Post

April 29, 2026

Long-Term Outcomes With Taletrectinib in ROS1-Positive NSCLC

As reported in the Journal of Clinical Oncology by Li et al, long-term follow-up of a Chinese phase II trial (TRUST-I) showed prolonged activity with taletrectinib in patients with ROS1 mutation–posit...

The ASCO Post

April 29, 2026

Long-Term Outcomes With Taletrectinib in ROS1-Positive NSCLC

The ASCO Post

April 29, 2026

Amivantamab in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer

In a phase Ib/II study (OrigAMI-1) reported in the Journal of Clinical Oncology, Oberstein et al found that the EGFR-MET bispecific antibody amivantamab-vmjw showed activity when used as monotherapy i...

The ASCO Post

April 29, 2026

Amivantamab in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer

The ASCO Post

Strategy for Managing Immunotherapy-Induced Parkinsonism in Patients With Multiple Myeloma

From the Journals

Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma

Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma

Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma

MIBC: Pembrolizumab With Trimodal Therapy for Bladder Preservation

MIBC: Pembrolizumab With Trimodal Therapy for Bladder Preservation

Daily News

MIBC: Pembrolizumab With Trimodal Therapy for Bladder Preservation

Long-Term Outcomes With Taletrectinib in ROS1-Positive NSCLC

Long-Term Outcomes With Taletrectinib in ROS1-Positive NSCLC

Amivantamab in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer

Amivantamab in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer

Recommendations

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Trending Now

Strategy for Managing Immunotherapy-Induced Parkinsonism in Patients With Multiple Myeloma

Trending Now

Find topic & conditions by first letter

Compendium

Inside Dental Hygiene

Inside Dental Technology

Inside Dentistry

The ASCO Post

JADPRO

JNCCN

JNCCN 360

Corneal Physician

Glaucoma Physician

New Retinal Physician

Ophthalmology Management

Ophthalmic Professional

Presbyopia Physician

Retinal Physician

The Ophthalmologist

Contact Lens Spectrum

Eyecare Business

Optometric Management

Presbyopia Physician

The New Optometrist

The Pathologist

From the Journals

Daily News

Recommendations